Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding changes in the interests of Judy Lewent, a Director of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of director share transactions and does not contain financial performance data.
Material Changes
The filing details the administration of a family member's estate by Director Judy Lewent, who served as Executor. On May 1, 2014, 500 American Depositary Shares (ADSs) held by the estate were transferred as follows:
- 167 ADSs were transferred by way of gift to each of Ms. Lewent's two brothers.
- 166 ADSs were transferred by way of gift to Ms. Lewent.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific share transactions described above in accordance with paragraph 3.1.4R(1)(a) of the Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Director Judy Lewent acted as Executor for a family estate involving 500 GSK ADSs.
- Transfers of these shares occurred on May 1, 2014, distributed as gifts to Ms. Lewent and her two brothers.
- The Company was advised of these transactions on May 1, 2014.
- This filing contains no financial results or operational updates for the period.